Evidence map›Paper›PMID 35073153›Full record

ArticleAnnals of internal medicine2022

What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2).

Amir Qaseem, Jennifer Yost, Itziar Etxeandia-Ikobaltzeta, Mary Ann Forciea, George M Abraham, Matthew C Miller, Adam J Obley, Linda L Humphrey, Scientific Medical Policy Committee of the American College of Physicians*, Elie A Akl and 6 more

Open access · greenAbstract read
In one paragraph

Article in Annals of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Amir QaseemAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.).ORCID 0000-0001-6866-7985
Jennifer YostAmerican College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.).ORCID 0000-0002-3170-1956
Itziar Etxeandia-IkobaltzetaAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.).ORCID 0000-0001-6606-649X
Mary Ann ForcieaPenn Medicine, Philadelphia, Pennsylvania (M.A.F.).ORCID 0000-0002-1999-1145
George M AbrahamUniversity of Massachusetts Medical School/Saint Vincent Hospital, Worcester, Massachusetts (G.M.A.).ORCID 0000-0003-4296-8362
Matthew C MillerPenn Medicine Radnor, Radnor, Pennsylvania (M.C.M.).ORCID 0000-0001-7267-4897
Adam J ObleyPortland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (A.J.O., L.L.H.).
Linda L HumphreyPortland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (A.J.O., L.L.H.).
Scientific Medical Policy Committee of the American College of Physicians*
Elie A Akl
Rebecca Andrews
Andrew Dunn
Ray Haeme
Devan L Kansagara
Mark P Tschanz
Scientific Medical Policy Committee of the American College of Physicians
Oregon Health & Science University · USAmerican College of Physicians · USMain Line Health · USPenn Center for AIDS Research · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

descriptionThe Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the current best available evidence on the antibody response to SARS-CoV-2 infection and protection against reinfection with SARS-CoV-2. This is version 2 of the ACP practice points, which serves to update version 1, published on 16 March 2021. These practice points do not evaluate vaccine-acquired immunity or cellular immunity.

methodsThe SMPC developed this version of the living, rapid practice points based on an updated living, rapid, systematic review conducted by the Portland VA Research Foundation and funded by the Agency for Healthcare Research and Quality. PRACTICE POINT 1: PRACTICE POINT 2: RETIREMENT FROM LIVING STATUS: Although natural immunity remains a topic of scientific interest, this topic is being retired from living status given the availability of effective vaccines for SARS-CoV-2 and widespread recommendations for and prevalence of their use. Currently, vaccination is the best clinical recommendation for preventing infection, reinfection, and serious illness from SARS-CoV-2 and its variants.

Indexed as

COVID-19PhysiciansAntibodies, ViralAntibody FormationCOVID-19 VaccinesHumansImmunity, InnateReinfectionSARS-CoV-2Antibodies, ViralCOVID-19 Vaccines

Identifiers

PMID35073153
PMCPMC8803138
OpenAlexW4206945034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.